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O reconhecimento por parte do receptor de células T (TCR) de 
péptidos processados e apresentados pelas células 
apresentadoras de antigénios (APC) via MHC envolve a formação 
de uma zona de contacto célula-célula, chamada sinapse 
imunológica. Após ativação das células T, diversas vias de 
sinalização celular são ativadas culminando na indução de 
transcrição génica. A glicoproteína de superfície, CD5, é 
considerada um inibidor da ativação via TCR, sendo uma das 
primeiras moléculas a ser recrutada para a sinapse imunológica 
após ativação da célula T. No entanto, até ao momento nenhum 
ligando na célula apresentadora de antigénios foi devidamente 
identificado e aceite como sendo o ligando do CD5. No nosso 
grupo, foi estabelecido que a sequência da cauda citoplasmática 
do CD5 que contém dois resíduos de tirosina (Y429 e Y441) é 
determinante para a sua função inibitória bem como para a 
translocação desta molécula para a sinapse imunológica. Neste 
projeto, propomos dissecar o papel de cada uma destas duas 
tirosinas nas propriedades modulatórias do CD5. Com esse 
propósito, foram introduzidas substituições na molécula do CD5, 
substituindo cada uma das referidas tirosinas por fenilalaninas. 
Estes mutantes foram expressos numa linha celular negativa para 
a expressão de CD5 endógeno e ajudarão a desvendar os 
mecanismos moleculares induzidos após ativação das células T e 
através dos quais o CD5 exerce o seu papel inibitório, avaliando 
por exemplo, fosforilação intracelular, fluxos de cálcio, e 
proliferação. Os nossos resultados nos ensaios de cálcio e de 
proliferação vieram confirmar o papel inibitório do pseudo-ITAM e, 
mais precisamente, da tirosina Y429. Estes mutantes serão 
também analisados por microscopia de fluorescência para avaliar 
a sua responsabilidade na mobilização do CD5 para a sinapse 
imunológica. Adicionalmente, será também monitorizada esta 
mobilização num mutante desprovido da porção extracelular, de 
forma a determinar a necessidade de estimulação por parte de um 
ligando expresso na célula apresentadora de antigénios. Um dos 
nossos resultados pioneiros mostram uma associação entre o CD5 
e a proteína adaptadora Crk, que poderá funcionar como uma 
ponte para outras interações. A proteína dependente de cálcio 
S100A4 também se associa com CD5 bem como a Fyn e Lck, 
levando-nos a propor que S100A4 controla os mecanismos de 
proliferação e de diferenciação de populações de células T 
auxiliares, dependentes de Lck e de Fyn, respetivamente, através 
de um mecanismo dependente do CD5. No futuro, CD5 poderá ser 
usado como alvo terapêutico com o objetivo de modular a resposta 
imune. 
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abstract 
 
 
 
 
 
 
 
 
 
T cell receptor recognition of peptide-MHC expressed on antigen 
presenting cells (APC) involves the formation of a tight cell-cell 
contact area, named immunological synapse. Upon successful T cell 
activation, several signal transduction pathways are triggered 
culminating with the induction of gene transcription. The T cell 
surface glycoprotein CD5, an inhibitor of TCR signaling, is one of the 
molecules that targets to the immunological synapse upon T cell 
activation, although no ligand in the APCs has yet been discovered. 
We have determined that a sequence containing two tyrosine 
residues (Y429 and Y441) within the cytoplasmic domain of CD5 is 
determinant both in the inhibitory function as well as in the synaptic 
localization of the molecule. In the current project we dissect the role 
of each of the two tyrosine residues in the modulatory properties of 
CD5. For this purpose, tyrosine-to-phenylalanine substitutions were 
introduced in the CD5 molecule, which was expressed in a CD5-
negative T cell line. These mutants will be relevant for unveiling the 
molecular mechanisms induced upon T cell receptor-mediating 
triggering, such as intracellular phosphorylation, calcium signals and 
proliferation. Our results in calcium and proliferation assays confirm 
the inhibitory role of the ITAM sequence, and more precisely, of the 
Y429 residue, although the other tyrosine may also play a somewhat 
lesser part. These mutants will also be analyzed by fluorescence 
microscopy for their ability to translocate to the immunological 
synapse upon T cell interaction with superantigen-loaded APCs. An 
additional CD5 mutant, one devoid of the extracellular domain, will 
also be monitored and will determine the requirement for an APC-
expressed ligand to induce CD5 translocation to the synapse. We 
found two new putative intracellular binding partners that can be part 
of, and help assembling, CD5 signalosomes. In vitro studies show 
that CD5 can associate with the adapter protein Crk, maybe acting 
as a bridge to other protein-protein interactions. On the other hand, 
the calcium-binding protein S100A4 also associates with CD5, Fyn 
and Lck. We hypothesized that S100A4 controls Lck-dependent T-
cell proliferation and Fyn-dependent differentiation of T helper 
subsets through a CD5-dependent mechanism, highlighting once 
again a putative role of CD5 as a molecular switch. In the future, 
CD5 can be used as a therapeutic target in order to modulate 
immune responses. 
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1. OVERVIEW OF THE IMMUNE SYSTEM 
 
The tissues, cells and molecules responsible for immunity constitute the 
immune system, which is in constant alert in order to protect our organism against 
the billions of microorganisms such as bacteria, viruses, parasites or fungi that we 
are constantly exposed to 1. A remarkable feature of the immune system is the 
capacity to distinguish between self and non-self, and to neutralize pathogens 
without damaging own tissues 1. 
There are two broadly defined types of immune responses in mammals that 
are complementary and partly overlapping 2. The first and early line of defense is 
provided by the innate arm of the immune system (phylogenetically the oldest 
defense system) 1. This is characteristically very fast and consists of cellular and 
biochemical defense mechanisms that are in place even before any threat appears, 
and is poised to respond rapidly to infections 1. This type of immunity is composed 
of physical and chemical barriers, phagocytic and natural killer (NK) cells, blood 
proteins and cytokines, all regulating many cellular activities of innate immunity 1. 
The innate system is not antigen-specific; however, it is able to discriminate 
foreign molecules from self 2. Phagocytes bear pattern-recognition receptors (PRRs) 
that identify structures termed pathogen-associated molecular patterns (PAMPs) 
present in microbe-derived molecules but not in host cells 3. PAMPs are usually 
molecules essential for the microorganisms to survive and therefore unlikely to be 
altered 3, such as components of fungal and bacterial cell-walls, β-glucan, 
peptidoglycans and lipopolysaccharides 4. PRRs have the advantage of being 
constitutively expressed in the host and of having the ability to detect pathogens at 
any given life-cycle stage. Specific PAMPs can be recognized by different PRRs, 
which activate particular signaling pathways 4. 
In addition to this first line of defense, a new type of response has emerged 
throughout evolution in vertebrates, the adaptive immune response. This type of 
response is characterized by very specific and more complex responses and is 
based on specialized antigen-specific groups of cells, the B and T lymphocytes 1. 
Each T or B lymphocyte (also known as T or B cells) expresses at their surface 
unique receptors that are specific to one given antigenic determinant, i.e., T cell 
receptors (TCR) or B cell receptors (BCR) expressed on individual cells are different 
from those of nearly all other T or B cells in the same animal and recognize different 
antigens. On the other hand, the adaptive response develops a memory that makes 
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future responses against the pathogen more quick and efficient 1. Firstly, antigens 
derived from the killing and phagocyte-intracellular processing of microbes are 
presented to and recognized by the antigen specific T or B cells, leading to cell 
priming, activation, differentiation and proliferation, which normally occurs in 
secondary lymphoid tissues. Secondly, the effector response against the pathogens 
takes place in the sites of disease/infection 1, 5. After the termination of the 
response, some of the expanded T and B cells remain in the system as memory 
cells, ensuring a fast response once and if the same pathogen re-infects the host 
later on in life 1. 
It is currently accepted that the innate and adaptive immune systems act 
together 2. In an initial phase, pathogens are identified, uptake and processed by 
specialized phagocytic cells such as dendritic cells or macrophages, and antigenic 
peptides are loaded into major histocompatibility complex (MHC) molecules and 
exposed at the cell surface to be presented for T and B cell recognition. Innate 
pathogen sensing and phagocytosis regulate cytokine production, MHC peptide 
presentation and co-stimulatory molecule expression in these so-called antigen-
presenting cells (APC). From the T lymphocyte side, recognition of a specific 
peptide presented in the context of an MHC complex of the APC leads to an efficient 
activation of naïve T cells. Furthermore, the antigen-specific cells amplify their 
responses by promoting innate effector mechanisms and recruiting innate immune 
cells to bring about the complete control of the invading microbes 5, 6. 
An illustration of how thin, and sometimes inexistent, is the separation 
between the innate and adaptive responses is exemplified by natural killer T cells 
(NKT) and γδ T cells, which are implicated in both types of immunity. NKT cells 
identify and neutralize potential pathogens without previous activation, being 
capable of detecting and responding even in the absence of expression of MHC 
molecules by the APC, thereby eliminating the cellular target and producing 
cytokines that give rise to other mechanisms of the immune response 7,8. The γδ T 
cells, which express a different form of TCR, mediate NK cell cytotoxicity 9 and 
phagocytosis 10.  
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2.  T LYMPHOCYTES 
 
T lymphocytes differentiate from progenitor cells in the bone marrow and then 
migrate to the thymus to mature. There, only T cells that do not react with self-
antigens presented by thymic epithelial cells or tissue macrophages are able to 
leave the thymus as mature naïve T cells 1. 
Two major types of effector T cells have been identified, T helper (Th) and T 
cytotoxic (Tc), bearing mutually exclusive CD4 or CD8 co-receptors on their surface, 
respectively. CD4+ Th cells are the orchestrating cells of the immune response, 
recognizing foreign antigens, producing cytokines and activating other parts of the 
cell-mediated immune response to eliminate the pathogen. They also play a major 
part in the activation of B cells. CD8+ cytotoxic cells are involved in antiviral and 
anti-tumor activity 5. 
 
 
Figure 1. Collaboration between innate and adaptive immunity.The immune system has two 
broadly defined types of immune response that work together, leading to complexes and efficient 
responses. The innate response, as a first line of defence, is faster and is activated through 
complement proteins, soluble factors and different effector cells, like macrophages, dendritic cells, 
granulocytes, mast cells and natural killers. As a second, and more complex response, emerged the 
adaptive arm of immune system, which introduced specificity and memory, with T and B cells as 
mainly intervenients. However these two types of response connect in some points. NKT and γδ T 
cells established the bridge between the innate and adaptive immune system. (Image from Dranoff, 
2004). 
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2.1. The major histocompatibility complex 
 The TCR only recognizes peptides processed and presented in the context of 
the MHC. There are two main types of MHC molecules, class I MHC and class II 
MHC that present protein antigens according to their origin 1. 
Antigens that are produced endogenously within the cell, like viral or tumor 
proteins, are processed into small peptides, transported into the endoplasmic 
reticulum and picked up by class I MHC molecules 11, 12. Upon presentation of 
antigen derived peptides, the immune system has the indication that these cells 
have been infected and need to be eliminated by cytotoxic CD8+ T cells, whose 
TCRs specifically recognize peptides in the context of this class of MHC 13. 
 Alternatively, specialized professional APCs (such as dendritic cells, 
macrophages and B cells) might have taken up exogenous antigens by endocytosis. 
Peptide fragments from the antigen enter in a specialized endosomal compartment 
thereby loading MHC class-II molecules and these peptide-MHC (pMHC) class II 
complexes are presented to helper CD4+ T cells 14. 
 In summary, as a result of their different function, MHC class-I is present in 
all nucleated cells and MHC class-II is only expressed by professional APCs 15. 
 
2.2. The TCR/CD3 complex 
T lymphocytes express at their surface a TCR, a clonotypic heterodimer 
responsible for the recognition of specific non-self antigens. Each TCR chain is a 
member of the immunoglobulin (Ig) superfamily, possessing one N- terminal variable 
and one constant Ig-like domain, followed by a connecting peptide, a 
transmembrane domain and a short cytoplasmic tail at the C-terminus. The TCR 
heterodimer consists of an α and a β chain (or γ and δ in a small subset of T cells) 
covalently bound by disulfide bridges 16, and this receptor recognizes only 
processed antigens that are presented at the surface of APCs as peptide fragments 
of the original antigen (γδ T cells do not recognize antigen in the peptide form 17).  
The TCR is found non-covalently bound to the transmembrane CD3 signaling 
complex, consisting of CD3γ, CD3δ, CD3ε and CD3ζ chains, (to form CD3δε and 
CD3γε heterodimers and the disulfide-linked ζζ homodimer) which activate the T cell 
after antigen contact 18. The presence of an antigen for the TCR-complex activation 
is necessary and the expression of all the components of the complex is 
indispensable for its assembly and recognition. The short TCR cytoplasmic tail has 
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no catalytic activity but the CD3 chains 
contain in their intracellular region 
specific sequences that are responsible 
for the initiation of the signaling 
cascade 1. 
 These regions are called 
immunoreceptor tyrosine-based 
activation motifs (ITAMs) and share a 
consensus sequence containing two 
important tyrosine residues 19. Each 
CD3 γ, δ or ε chain contains one ITAM 
whereas ζ chains have three ITAMs per 
chain. ITAMs are phosphorylated by 
the Src family kinase lymphocyte-
specific tyrosine kinase (Lck) that is 
tightly associated with either the CD4 
or CD8 co-receptors, and each doubly-
phosphorylated ITAM becomes a 
docking site for the ζ-chain associated 
protein of 70 kDa (ZAP-70), a protein 
tyrosine kinase containing two Src-
homology 2 (SH2) domains 20, 21. 
Triggering of the T cell receptor and ZAP-70 docking initiate a signaling 
cascade that results in the partial activation of the T cell. Several signal transduction 
pathways that involve protein kinases and phosphatases, second messengers and 
key intermediates, are then triggered, contributing to the induction of gene 
transcription according to the defined genetic programs that are characteristic of the 
different T cell subsets, and to the differentiation and proliferation of these cells 16. 
 
2.3. T cell-APC interactions 
After capturing a protein antigen in epithelia and tissues, APCs transport 
these antigens to draining lymph nodes where they wait for the arrival of circulating 
naïve T cells having TCRs specific for the displayed MHC-peptide complex 13. 
Conversely, T cells continuously circulate throughout the peripheral lymphoid 
Figure 2. The TCR/CD3 complex. The T-cell 
receptor is a cell surface heterodimer consisting of 
an α and a β chain covalently bound by disulfide 
bridges. The TCR only recognize processed 
peptides presented by an APC in the context of 
MHC. This interaction is stabilized by the bound of 
the kinase Lck in the proximity of the TCR–CD3 
complex. Lck can then phosphorylate the CD3-
associated immunoreceptor tyrosine-based 
activation motifs (ITAMs). (Image from Gascoigne, 
2008). 
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organs, searching for APCs that present a foreign peptide for which their TCR is 
specific 22. 
The first interaction between the APC and the T cell is mediated by adhesion 
molecules expressed in both cells that allow a physical contact, allowing the T cell 
to scan the APC in order to recognize the peptide presented by the MHC 13. 
The recognition of the pMHC by the TCR is very specific but not enough to 
induce complete activation of the T cell. It can even, under some conditions, lead to 
T cell anergy. Costimulatory signals are 
thus essential for the full activation of 
the T cell 23, 24. The signals generated 
by TCR recognition of pMHC, together 
with signals derived from the interaction 
of the T cell costimulatory CD28 with its 
APC-expressed ligands CD80 or CD86 
(also designated as B7.1 and B7.2 
respectively) will induce the complete 
activation of the T lymphocyte 25, 26. 
Upon phosphorylation of specific 
tyrosine residues of the intracellular 
part of CD28, additional signaling 
proteins are recruited, and these 
signals are the beginning of the co-
stimulatory cascade 11. This pathway 
begins when CD28 interacts with its 
counter receptor and, despite lacking 
enzymatic activity by itself, CD28 can 
be phosphorylated also by Src-family 
kinases, resulting in an increase of the association between CD28 and 
Phosphatidylinositol 3-kinase (PI3K), IL-2-inducible T cell kinase (Itk) and Growth 
factor receptor-bound protein 2 (Grb2) 27. Later, with the assembly of this net of 
interactions, cytosolic calcium increases, the Mitogen-activated protein kinase 
(MAPK) signaling pathway is initiated and specific transcription factors are 
activated, which will determine the fate of the T lymphocyte 28, 29. 
 CD28 has a homolog that exerts an inhibitory effect during T cell activation. 
This homolog is the cytotoxic T lymphocyte associated protein-4 (CTLA-4) 30. The 
 Figure 3. Key signaling molecules that are 
involved in T-cell recognition. The stimulatory 
peptide-MHC molecule is shown in red, establishing 
a ligation with TCR/CD3 complex. The 
activatory/costimulatory molecules are represented: 
on blue, by the other hand, inhibitory molecules are 
shown in yellow. There are other important 
molecules that influence the type of response 
without contributing to signaling, represented in 
grey. (Image adapted from Huppa and Davis, 
2003). 
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competition between CTLA-4 and CD28 for the same two ligands (CD80/CD86) 
together with the superior affinity of CTLA-4, results in the replacement of CD28 
binding and consequently down modulates T cell activation 31. 
Apart from the co-receptors (CD4 or CD8) and costimulators (CD28) or 
repressors (e.g., CTLA-4), a number of other essential molecules will influence the 
type of response, such as CD2, Lymphocyte function-associated antigen 1 (LFA-1), 
CD44 and CD45, among others 16. 
 
2.4. The immunological synapse and T cell signal transduction 
Upon recognition of peptide-MHC complexes by the TCR, a stable cell-cell 
interface is formed between the T cell and the APC involving an extensive 
rearrangement of the plasma membranes of both cells, and is named the 
immunological synapse (IS) 32. To maintain this stable architecture, diverse 
structural changes are required that lead to a dynamic action of the actin 
cytoskeleton and the activation of adhesion receptors in these areas 32, 33.  
The first studies using fixed-cell imaging revealed that the IS is organized in a 
“bull’s eye” pattern 33, 34 with a central cluster containing TCR-pMHC pairs. This area 
is termed the central supramolecular activation complex (c-SMAC) and is the place 
where coreceptors  (CD4 and CD8), the costimulatory receptor CD28 and small low-
affinity adhesion receptors such as the CD2-CD58 pair, can be found 33, 35. This 
region is surrounded by a peripheral supramolecular activation complex (p-SMAC), a 
ring mainly composed by integrins like the LFA-1 and, on the APC side, its ligand 
intercellular adhesion molecule 1 (ICAM-1) 33. The large CD45 glycoprotein shows a 
particular behavior, it is recruited to the c-SMAC at an early time point, possibly to 
activate Lck, and later on moves to a more peripheral region than the p-SMAC. This 
farther region is termed distal-SMAC (d-SMAC), being the place where most other 
large molecules such as CD43 are localized 36. 
These first studies also implied that TCR signaling was initiated and sustained 
at the c-SMAC. However, this view has been gradually changing, and supported by 
several mechanistic and structural studies, currently it is thought that T cells can be 
activated in the absence of c-SMAC formation 33. 
 Just within a few minutes upon TCR triggering and TCR/CD3 complex 
activation, there occurs a distribution of the different T cell surface receptors and an 
extensive membrane reorganization, driven by actin remodeling and polymerization 
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processes 37. The central role of actin involves its attachment to proteins and 
positioning them into the center of the IS 38.  
TCR microclusters formed immediately after the recognition of pMHC were 
described as responsible for the initiation and sustaining of TCR signaling, being 
sufficient to increase intracellular concentration of calcium 39, 40.  
However, the exact mechanism of selective TCR triggering remains unclear 
and many models have been proposed. According to the molecular mechanism 
these models can be divided into aggregation 41, conformational change 42 and 
kinetic segregation 43. These models are explained in more detail in Figure 4 44. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. TCR triggering models. A and B. Aggregation models. In the co-receptor 
heterodimerization model (A), a co-receptor is responsible for allowing Lck to be in close proximity 
with the TCR/CD3 ITAMs by binding the MHC. In the pseudodimer model (B), a dimer is formed when 
a self-pMHC and an agonist pMHC bind adjacent TCRs, and the co-receptor brought by the TCR-self-
pMHC pair engages the agonist pMHC. C and D. Conformational change models. A piston-like 
conformation (C) is adopted by the TCR/CD3 complex upon mechanical effects of pMHC binding, 
leading to a conformational change in the CD3 cytoplasmic domains. The induced clustering model 
(D) allows an increase in kinase activity targeting the TCR/CD3 ITAMs. E. The kinetic segregation 
model postulates that inhibitory tyrosine phosphatases are segregated from the close-contact zone 
formed between T cells and APCs upon TCR binding to pMHC, enhancing phosphorylation of the 
TCR/CD3 ITAMs. (Image from van der Merwe and Dushek, 2011). 
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Once T cell activation is initiated, the TCR signaling pathway (Fig.5 45) begins 
with the recruitment of Lck, which promotes the phosphorylation of Fyn, and both 
induce the phosphorylation of TCR/CD3 ITAMs 20. After these initial steps, ZAP-70 is 
recruited to the doubly-phosphorylated ITAM 
tyrosines, and is in turn 
phosphorylated and activated 46. 
Activation of ZAP-70 results in 
the phosphorylation of linker for 
activation of T cells (LAT), which 
works as signaling docking 
platform for phospholipase C-γ1 
(PLC-γ1), PI3K and SH2 domain-
containing leukocyte protein of 
76kDa (SLP-76) 47, 48. 
 Later, with the assembly 
of this network of interactions, 
several signal transduction 
pathways that involve protein 
kinases and phosphatases, 
second messengers and key 
intermediates, are triggered, 
cytosolic calcium increases and 
the MAPK signaling pathway is 
initiated. All together these 
events culminate in the induction 
of transcription factors that are 
translocated to the nucleus, 
leading to differentiation, 
proliferation and actin reorganization responses, which will determine the fate of the 
T lymphocyte 20, 29, 49. 
This system is tightly regulated and mechanistic failures or imbalances may 
lead to severe consequences such as autoimmunity, allergies, and chronic 
infections, these being some of the reasons why the regulation of T cell activation 
mechanism has being a highly investigated topic 50. 
 
Figure 5. Schematic representation of the T cell signal 
transduction. Upon TCR triggering and the engagement of 
costimulatory receptors, Lck promotes Fyn phosphorylation and 
both induce the phosphorylation of CD3 ITAMs. This leads to the 
recruitment of ZAP-70 and consequently to the phosphorylation 
of LAT. PLC-γ1, PI3K and SLP-76 docks to LAT and 
recruit/activate different effectors. Membrane 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) releases 
diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (InsP3) that 
induce calcium release. These events activate downstream 
transcription factors such as NF-κB, NFAT and AP1. (Image 
adapted from Friedl et al., 2005). 
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3. THE INHIBITORY SURFACE GLYCOPROTEIN CD5 
  
CD5 is a T cell surface glycoprotein that represses tyrosine phosphorylation-
mediated signal transduction pathways and modulates cellular activation. Its 
expression is restricted to thymocytes, mature peripheral T cells and also to a 
subset of mature B cells (B-1 a cells) 51. CD5 was also one of the first surface 
markers used to identify T cells due to it early appearance in thymocyte 
development 52. 
 CD5 is a type I transmembrane 
glycoprotein with a molecular mass of 67kDa and 
belongs to the highly conserved scavenger 
receptor cysteine-rich superfamily (SRCR-SF) 53. 
Structurally, CD5 has an extracellular region with 
348 amino acids organized in three SRCR 
domains, an hydrophobic transmembrane 
sequence of 29 amino acids, and a 94 amino 
acid-long cytoplasmic tail 53. The cytoplasmic 
domain of CD5 is highly conserved and contains 
multiple serine and threonine residues and four 
tyrosine residues (at positions Y378, Y429, Y441 
and Y463). Of these, three are potentially 
embedded into known tyrosine-based 
phosphorylation motifs 54. The amino acid 
sequence surrounding Y429 and Y441 resembles 
an ITAM, differing in only one residue from the 
ITAM consensus sequence 55. On the other hand, 
residues Y378 and Y441F are often considered to 
be part of an immunoreceptor tyrosine-based 
inhibitory motif (ITIM) 56. 
Upon TCR triggering, residues Y429 and Y463 are phosphorylated with very 
rapid kinetics 57-59, with the protein tyrosine kinase Lck (the kinase that coincidently 
phosphorylates the TCR/CD3 ITAM motifs) playing a major role in these 
phosphorylation events59-61. Two other protein tyrosine kinases, Fyn and Itk, may 
additionally contribute to CD5 phosphorylation or even regulate this Lck function48. 
 
Figure 6. SRCR-SF group B members. 
CD5 with three SRCR domains 
(represented as grey trapezoid) in the 
extracellular part, a transmembrane 
region and a cytoplasmic tail. (Image 
adapted from Gonçalves et al, 2009). 
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Several candidates for being CD5 ligand have been described. The first 
reported ligand was a C-type lectin expressed in B cells, CD72 62. Other APC 
potential ligands were described later, such as gp40-80 63, gp150 64and IgV(H) 
framework sequence region 65. However, since the interactions of these proteins 
with CD5 were never independently confirmed, the CD5 ligand remains unknown. 
Recently, CD5 has been show to establish homotypic interactions 66.  
From a biological and functional point of view, CD5 was initially proposed to 
behave as a costimulator 67 but later was found to be in fact an inhibitory molecule 
68. The first in vitro studies indicated that CD5 was capable of enhancing TCR-
mediated cell proliferation in peripheral T cells, working as a costimulatory molecule 
67. However the generation of a CD5 knockout mouse uncovered its inhibitory role, 
with the mice revealing a hyperresponsive phenotype to thymocytes and peripheral 
T cells. In parallel with the increase in proliferation, mice with a disrupted CD5 gene 
exhibited enhanced phosphorylation of signaling effectors such as LAT, PLC-γ1 or 
Vav, in response to TCR stimulation 68, 69. 
The integrity of the cytoplasmic domain of CD5 was shown to be crucial for its 
inhibitory role during thymocyte development 52. Also, the levels of CD5 expression 
on T cells nearly correlate with the avidity of antigen-specific receptors on T cells 
being important during T cell development 70. B cells can also modulate CD5 
expression by switching the use of exon 1 to alternate between a CD5 membrane-
bound form and a CD5 cytoplasmic-expressed form 71. 
 
3.1. Phosphorylation and binding partners for CD5 
The inhibitory role of CD5 was first described to result from the docking of 
SH2 domain-containing protein tyrosine phosphatase 1 (SHP-1) (phosphatase with 
two SH2 domains and with an important inhibitory role in TCR signaling 72) to the 
phosphorylated residue Y378 of CD5 56. This association was reported in the Jurkat 
T cell line, in murine thymocytes and also in B-1a cells 56,73,74, but the fact that CD5 
mutants that do not contain this residue still retain the capacity of inhibiting 
signaling 75, 76 led to the conclusion at the time that SHP-1 was not the only mediator 
of the inhibitory effects of CD5. 
At the surface of T cells, CD5 also associates with CD2, which may enhance 
the inhibitory function of CD5 by the enhancement of the SHP-1 activity 73, 76. 
However, other molecules were independently described to associate with the 
cytoplasmic tail of CD5, potentially conferring additional negative regulatory 
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activities, such as RasGTPase activating protein (RasGAP), Cbl, Akt and Casein 
kinase 2 (CK2) 55, 77-79. The CD5 tyrosine residues within ITIMs are Y378 and Y441, 
although curiously it has been pointed out that it is the residue Y429, which harbors 
these molecules that down-modulate cellular activation in thymocytes, such as 
RasGAP and Cbl 55, 80, 81. 
CD5 signaling additionally activates a pathway that involves PI3-kinase, with 
the two SH2 domains of PI3-kinase binding to phosphorylated Y441 and Y463, and 
depending on the signaling 
environment, this association 
can also promote inhibitory 
effects 55, 82. 
As described above, Lck is 
the kinase responsible for the 
phosphorylation of CD5 at 
residues Y429 and Y463. It has 
been long known that CD5 is 
rapidly phosphorylated upon 
TCR stimulation 83, but since the 
TCR/CD3 complex does not 
include Lck, this described 
interaction between CD5 and Lck 
could be promoted in assembled 
signaling micro-domains, such 
as lipid rafts 60. Therefore, 
receptors like CD5 may act as 
scaffolds leading to the 
interaction between distinct 
types of rafts and their 
components 84. In such a role, 
we have observed that upon 
activation, CD5 associated with the Src-type kinase Fyn in lipid rafts 60.  
Phosphorylation of the C-terminal Y531 residue of Fyn leads to a considerable 
reduction in its kinase activity 85. This effect can be obtained through the activation 
of CD5 and involves the distal region of the cytoplasmic domain of CD5. Since C-
terminal Src kinase (Csk) is the only kinase described to phosphorylate Fyn at this 
Figure 7. CD5-mediated interactions with endogenous 
and/or exogenous ligands. The extracellular part of CD5 
establishes interactions with the described ligands and with itself 
(homotypic interaction). In the cytoplasmic tail, pseudo-ITAM is 
shaded in orange. Intracellular signaling molecules with activation 
roles that interact with the CD5 cytoplasmic tail are: Lck, PI3K; 
with inhibitory roles: c-Cbl, Ras-GAP, SHP-1; and a prosurvival 
molecule: CK2. (Image adapted from Soldevila et al, 2011). 
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C-terminal inhibitory tyrosine residue, we anticipated that CD5 could associate with 
Csk. However, we were not able to detect such an association between CD5 and 
Csk. One other possibility was that the CD5-Csk interaction was indirect and might 
be mediated by the membrane-bound adapter phosphoprotein associated with 
glycosphingolipid-enriched microdomains (PAG), which binds the distal part of the 
CD5 cytoplasmic tail. Interestingly, these associations, while promoting Fyn’s Y531 
phosphorylation and decreasing Fyn activity, also induced the disruption of a 
signaling loop involving Fyn, Csk and PAG. All this set of complex events 
contributed to confer yet another additional alternative role in signaling inhibition to 
CD5 60. 
In summary, it seems that CD5 may inhibit early TCR signaling via several 
pathways. CD5 may associate with SHP-1, which by inhibiting ZAP-70 activity, 
directly promotes itsdephosphorylation86, 87. In parallel, CD5 may inhibit Fyn, which 
is also important for the activation of ZAP-70 60. 
 
3.2. CD5 at the Immunological Synapse 
CD5 is one of the molecules that accumulates at the IS during antigen 
recognition 88. During the formation of the IS, CD5 co-localizes with TCR/CD3 
complexes and is able to refrain T cell signaling without decreasing T-cell/APC 
adhesion or impairing IS formation. The inhibitory effect has been assigned to the 
ITAM-like motif of CD5 and is augmented by the increase in the level of CD5 
expression at the membrane. However, in these studies it was not described 
whether CD5 translocation to the synapse was due to the binding of a CD5-ligand 
expressed on the APC or due to CD5 intracellular interactions within the T cell 89. 
Recent observations from our group suggested that when the possible interactions 
with unknown ligands are disrupted, CD5 is still able to translocate to the IS and this 
movement is dependent on specific key motifs of its cytoplasmic tail. Another study 
evidenced that CD5 can also be rapidly recruited to the contact zone in an Ag-
independent manner 89, uncovering a possible function for CD5 in early T cell 
activation even before the complete formation of the IS 37. 
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4. CRK, AN ADAPTER PROTEIN IN IMMUNE RESPONSES 
 
Adapter proteins are important players in most signaling pathways, acting as 
scaffolds making the assembly of large protein complexes. Adapter proteins do not 
have catalytic activity. 
 The adapter molecule CT10 Regulator of Kinase (Crk) belongs to a protein 
family that binds to several tyrosine-phosphorylated proteins through SH2-
phosphotyrosine interactions 90. Crk adapter proteins include three family members: 
CrkI and CrkII arise from the alternatively spliced Crk gene, and CrkL is encoded in 
the Crk-like gene 91. CrkI lacks the regulatory phosphorylation site and the SH3 
domain in the C-terminal, although CrkII and CrkL contain one SH2 domain and two 
SH3 domains (in the N- and C-termini) 92, however the functions of the different 
domains still remain controversial. 
In T lymphocytes, Crk has been reported to form multiprotein complexes 
through TCR stimulation. One of the most described interaction in T cells is with Cbl. 
Upon TCR stimulation, Cbl becomes tyrosine-phosphorylated and associates with 
Crk and this association is involved in the negative regulation of the TCR 93, 94. Cbl 
is a ligase that catalyzes protein ubiquitynation (a process of substrates degradation 
by the proteasome) of signaling effectors and their subsequent degradation in the 
proteasome complex, therefore acting as a negative regulator of T cell activation 95, 
96. However the exact mechanism of how the phosphorylated Crk regulates TCR 
signaling remains unclear. Crk also exerts some important roles in T cell cytokine 
signaling 97, in B cell and NK-cells regulation 98,99. 
 
 
5.  S100A4, A CYTOPLASMIC CALCIUM-BINDING PROTEIN 
 
Appropriate T-cell responses and the strength of TCR-pMHC interactions are 
connected to cytoskeleton reorganization, where filamentous actin and nonmuscle 
myosin II (NMMII) play a major part 100, 101. Activation of the TCR recruits effector 
molecules, with the kinases Lck and Fyn playing a central role in transducing 
TCR/CD3-mediated signals by phosphorylating ITAMs, activating the tyrosine kinase 
ZAP-70 102, and recruiting cytoskeletal remodeling factors of the Rho GTPase family 
to the inner leaflet of the cell membrane. Rho GTPases are coupled to actin and 
NMMII, and define the duration of TCR activation 100, 101. Suppression of the NMMII 
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function abolishes formation of TCR clusters at the outer edge of the T cell 103 and 
reduces the activity of Src-tyrosine kinases in T cells 104. 
S100A4 is a small Ca2+-binding protein known for its metastasis-promoting 
properties, but it is required for normal cell-to-cell interactions and cell motility. The 
function of S100A4 relies on its interactions with the cytoskeletal proteins NMMII, F-
actin, and tropomyosin. Binding of S100A4 to these proteins occurs in a Ca2+-
dependent manner and inhibits the actin-regulated ATPase activity of myosin II 105, 
106. The disassembly of myosin filaments occurring as a result of S100A4 binding 
has a major impact on cytoskeletal rearrangements, cell polarization, shape 
changes, and motility 105, 107, 108.  
The interaction between S100A4 and NMMII, beta-liprin or and the 
cytoplasmic domain of FcγRIIIA, occurs within protein kinase C (PKC) or CK2 
sensitive regions of the target proteins 105, 106, 108. On the other hand, the cytoplasmic 
tail of CD5 contains a PKC-sensitive region at S427 and a CK2 phosphorylation site 
at its C-terminal region109. A deletion of the C-terminal fragment of CD5 containing 
the CK2-phosphorylation site results in the failure to produce the Th2 and Th17-cell 
subsets 109, and moreover, CD5 knock-out mice have a very similar phenotype to 
that presented by mice with a disrupted S100A4 gene, suggesting a functional 
coupling between the two molecules 79, 110. 
Deficiency in S100A4 is associated with a smaller CD5+CD4+ T-cell 
population, which presents also low intensity of active pY429 CD5 expression on the 
T cell membrane. A functional consequence of insufficient CD5 in S100A4-deficient 
mice may be found in the enhanced lymphocyte proliferative capacity observed in 
S100A4-defficient mice; however, binding assays revealed only a weak interaction 
between S100A4 and a CD5 peptide containing the CK2-sensitive sequence. 
Nevertheless, a functional interaction between CD5 and S100A4 may be indirect, 
possibly involving other CD5-binding partners, and is worthy to be further explored. 
 
6. AIMS OF THIS THESIS 
 
The immunomodulatory function of CD5 in T cell activation suggests that it 
can play a major role in disease processes such as autoimmunity and cancer. A 
comprehensive understanding of how CD5 exerts its regulation, including the 
identification of its signaling partners, is still missing. 
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The main goal of this thesis is to extend the knowledge of the CD5 function by 
dissecting the interactions established through the cytoplasmic tail and evaluate how 
determinant each tyrosine residue is in early and late signaling events. 
It was also a long term objective of our line of research to determine the 
molecular features regulating the translocation of CD5 to the immunological synapse 
upon T cell-APC interactions. For that purpose, we are evaluating whether the 
extracellular domain, the intracellular tyrosine residues, or both, are critical for 
synapse targeting. 
Our ultimate goal is to define whether CD5 is a genuine signaling regulator or 
whether its function may resemble a membrane adapter that could possibly induce 
different responses depending on the assembled CD5 signalosome. 
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Plasmid constructs 
Full-length cDNA of human CD5 was amplified by PCR from a template in the 
CD5-pGFP-N1 vector kindly provided by G. Bismuth (Institut Cochin, Paris). To 
make the desired deletion of the ITAM-like motif (YSQPPRNSRLSAYPAL) in the 
CD5 cytoplasmic domain, or to mutate tyrosine residues into phenylalanines, 
mutagenic oligonucleotides were used according to the manufacturer’s protocol of 
the QuikChange site-directed mutagenesis kit (Stratagene).  
A lentiviral expression vector based on pHR-SIN 111 encoding citrine 
downstream of the insertion site was used. CD5 wild-type and mutants were cloned 
into this vector using the MluI and BamHI restriction sites for constructs with citrine, 
and using MluI and NotI restriction sites for constructs without citrine. The accuracy 
of the sequences of if the final constructs was checked by sequencing. 
 
Cell lines 
Cell lines Jurkat TAg (JTAg), Raji, E6.1, as well as JTAg cell lines stably 
transfected with human CD5 mutants were maintained at 37 ºC and 5% CO2in RPMI 
1640 culture media supplemented with 10% fetal bovine serum (FBS), 1 mM sodium 
pyruvate, 2 mM L-glutamine, penicillin G (50 U/ml) and streptomycin (50 μg/ml). 
Human embryonic kidney HEK293T cells112 were grown at 37°C in a 5% CO2 
humidified chamber, in Dulbecco’s modified Eagle’s medium (DMEM) containing 
10% FBS, 1 mM sodium pyruvate, 2 mM L-glutamine, penicillin G (50 U/ml) and 
streptomycin (50 μg/ml). 
 
Lentiviral transduction 
HEK-293T cells112 were transiently transfected with pHR-SIN vector 
constructs, together with pMD.G and p8.91 lentiviral vectors 113 in 6-well plates 
using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s 
instructions. Supernatant was harvested at 72 h after transfection and centrifuged at 
1,800xg for 5 min at RT to remove any debris from supernatant. 1x106CD5-deficient 
JTAgcells114 were platted into a T25 flask with 2 ml of fresh complete RPMI 1640and 
left to transduce with lentiviral supernatants overnight. Cells were maintained at 37 
°C in a 5% CO2 humidified incubator. 
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Antibodies 
 Monoclonal antibodies (mAb) used were: mouse anti-human CD5 Y2-178 
(Santa Cruz Biotechnology); mouse anti-human CD3 clone OKT3 (Exbio); mouse 
anti-human CD28 clone 28.2 (Exbio); mouse anti-human CD6 clone Mem98 (Exbio); 
rabbit anti-human CD5 RabmAb (Abcam); mouse anti-human CD69 APC-conjugated 
(eBioscience); mouse anti-human CD3 PerCP-Cyanine5.5 conjugate (eBioscience). 
Isotype control mouse anti-human C23 (Santa Cruz Biotechnology).Polyclonal 
antibodies were: rabbit anti-human Crk (Abcam); rabbit anti-human S100A4 (Dako); 
rabbit anti-human Csk (Santa Cruz Biotechnology); rabbit anti-human Fyn (BL90) 
and rabbit anti-human Lck (DA3) were given by J. B. Bolen and M. G. Tomlinson 
(University of Birmingham). Secondary antibodies were: goat anti-rabbit peroxidase 
conjugate (Sigma); IgG VeriBlot anti-rabbit for immunoprecipitation assay (IP) 
peroxidase conjugate (Abcam); donkey anti-mouse IgG conjugated with Alexa Fluor 
647 (Life Technologies). 
 
Flow cytometry analysis 
For the detection of surface receptors, 5 x 105cells were washed twice in ice-
cold phosphate-buffered saline (PBS) containing 0.2% bovine serum albumin (BSA) 
and 0.1 % NaN3 (PBS/BSA/NaN3). Cells were incubated with primary antibodies 
diluted at proper concentrations in PBS/BSA/NaN3and incubated on ice for 30 min. 
Cells were washed and stained with secondary antibodies, if applicable, for 
additional 30 min on ice and protected from daylight. At the end, cells were 
resuspended in PBS/BSA/NaN3and 10,000 live cells were collected on a 
FACSCalibur (BD Biosciences). The data were analyzed using the FlowJo software 
(Treestar).  
 
Fluorescence-activated cell sorting 
In order to have the different JTAg CD5 mutants expressing equivalent 
amounts of surface CD5 and CD3 throughout the different cells, 1 x 107 cells were 
centrifuged for 5 min at 300 x g and washed twice with PBS/BSA/NaN3. Cells were 
stained for CD5 and CD3 surface expression using an IgG1 mouse anti-human CD5 
mAb (Y2-178, Santa CruzBiotechnology) followed by a donkey anti-mouse IgG-Alexa 
Fluor 647 conjugated (Life Technologies) and an IgG2a mouse anti-human CD3 
conjugated with PerCP-Cy5.5 (eBioscience). Cells were washed and ressuspended 
in PBS containing 5 mM ethylenediaminetetraacetic acid (EDTA), 25 mM 4-(2-
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hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 2 % FBS and sorted on 
a FACSAria 1 cell sorter (Becton Dickinson). In some cases, the levels of citrine 
fluorescence were also taken into account to perform the sorting.  
 
Fluorescence microscopy and analysis of CD5 membrane localization 
JTAg cell lines stably transfected with human CD5 mutant cDNAs in frame 
with citrine fluorescent protein were plated on poly-L-lysine-coated glass coverslips 
for 30 min at 37°C. Cells were then washed and fixed in 4 % paraformaldehyde 
(PFA) in PBS at RT for 10 min. Following washing, cells were counterstained with 
the nuclear dye 4',6-diamidino-2-phenylindole (DAPI; Life Technologies)and 
mounted on a glass slide. Immunofluorescence and transmission light images were 
acquired on an Zeiss Axio Imager Z1 fluorescence microscope (Carl Zeiss) equipped 
with an AxioCam MR 3.0 video camera (Carl Zeiss) and Axiovision 4.7 software 
(Carl Zeiss, Germany). 
 
Intracellular calcium flux 
To measure total intracellular calcium release as a measure of cell activation 
in JTAg cells expressing the different CD5 mutants, 3 x 106 cells were loaded with 
the calcium indicator Fluo-4 (Molecular Probes, Life Technologies) at the final 
concentration of 5μM in complete RPMI and incubated for 30 min at 37 ºC with 
agitation. After this, cells were washed with PBS/BSA/NaN3 and the basal calcium 
levels were analyzed by flow cytometry in the FACSCalibur analyzer (BD 
Biosciences) for 1 min followed by addition of 2 μg/mL of the agonist CD3 mAb 
OKT3 (Exbio) and sample monitoring for calcium release during 6 min. As positive 
control, 2 μg/ml ionomycin (Calbiochem) was added to open all calcium channels. 
Analysis was performed using FlowJo.  
 
Measurement of CD69 expression 
JTAg cells expressing CD5 mutants were plated on a 96-well plate at a 
concentration of 5 x 105 cells per 100μl of complete RPMI. Cells in one half of the 
wells were kept in resting conditions whereas on the other half were activated with 2 
μg/ml of OKT3and 5 μg/ml of the CD28 mAb 28.2 (Exbio). 10 μg/ml of 
phytohemagglutinin (PHA) was used as positive control for T cell activation. Cells 
were incubated at 37 ºC for 12 h and stained with mouse anti-human CD69 APC-
conjugated (eBioscience) for 30 min. After washing, cells were ressuspended in 
METHODS 
 
 24
PBS/BSA/NaN3and data was collected on a FACSCalibur (BD Biosciences). The 
data were analyzed using FlowJo. 
 
Proliferation assay 
The different JTAg cells (untransfected and transfected with different CD5 
cDNA mutants) were subjected to serum deprivation for 24h to synchronize the cell 
cycle. Cells were then stained with carboxyfluorescein succinimidyl ester (CFSE) 
using a cell proliferation kit (Molecular Probes, Life Technologies) and resuspended 
in 1 ml of PBS/BSA/NaN3. 200 μl of the cell suspensions were used to mark the 0 
time point and the remaining was left in culture. Samples were analyzed after 24, 48 
and 72 h. Cells were stained with 0.5 μg/ml of propidium iodide (PI) (Sigma) and 
data were collected on a FACSCalibur. The data were analyzed using FlowJo. 
 
Cell conjugation formation 
Raji B cells were incubated with a mix of superantigens (staphylococcal 
enterotoxins SEE, SEA, SEB and SEC3, 200 ng/ml each; Toxin Technologies) and 
plated on poly-L-lysine-coated glass coverslips for 30 min at 37°C. Jurkat cells were 
added to these APCs and then incubated at 37°C for 45 min to promote cell-cell 
interactions. Cells were fixed with 4% PFA in PBS for 10 min and washed several 
times with PBS before analysis. Cells were washed, counterstained with DAPI and 
mounted on a glass slide. Immunofluorescence and transmission light images were 
acquired on a Zeiss Axio Imager Z1 equipped with an AxioCam MR 3.0, and 
analyzed using the Axiovision 4.7 software. 
 
Cellular activation/Pervanadate treatment and immunoprecipitation of 
CD5 in Jurkat cells 
4 x 107 E6.1 Jurkat cells were used per condition. Pervanadate was freshly 
prepared by mixing sodium orthovanadate 100 mM (Sigma-Aldrich) and H2O2 at a 
final concentration of 0,6%, 10 minutes before addition to cells at a final 
concentration of 100 μM. Cells were activated for 2 or 10 minutes with pervanadate 
at 37 °C. In parallel experiments, E6.1 cells were activated with 5 μg/ml OKT3 
F(ab)’2 during 2 and 10 min at 37 ºC.  
Cells were lysed for 30 min on ice in lysis buffer [10 mM Tris-Cl (pH 7.4), 150 
mM NaCl, 1 mM EDTA, 1 mM PMSF, and 1% (v/v) Triton X-100]. The nuclear pellet 
was removed by centrifugation at 11,000 x g for 10 min at 4 °C, and the 
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supernatants were precleared by end-over-end rotation with protein A-Sepharose 
CL-4B beads (Amersham Biosciences) for 30 min at 4 °C. 5 μg of Y-2/178 and 100 
μl of 10 % protein A-Sepharose beads were added to the samples and rotated for 90 
min at 4 °C. The beads containing the immune complexes were washed three times 
in 1 ml of lysis buffer 
Samples were boiled for 5 min in SDS buffer and run on 11% SDS-PAGE. 
 
In vitro kinase assays and precipitation of phosphorylated CD5 peptides 
Between 1 and 3 x 107 E6.1 Jurkat cells were lysed and immunoprecipitated 
as described in the section above. Antibodies used for immunoprecipitation (2 μl 
anti-sera antibody) and immunoblotting were polyclonal anti-Fyn (BL90), anti-Lck 
(DA3) and anti-Csk. In the end of the immunoprecipitation, beads containing the 
immune complexes were washed 3 times in 1 ml of lysis buffer and 2 additional 
times in kinase assay buffer (25 mM HEPES and 0.1 % detergent). Triton X-100 
assay buffer (30 μl) containing 10 mM MnCl2, 1 mM sodium vanadate, 1 mM NaF, 
and 50 μCi (185 KBq) of [γ-32P]-ATP was added to the immune complexes, and in 
vitro kinase reactions were allowed to occur for 15 min at 25 °C. Reactions were 
stopped by the addition of 30 μl of 2 % SDS buffer after which the samples were 
boiled for 5 min. Products were separated on SDS-PAGE gels, and autoradiography 
of the dried gels was done with BioMax MR films (Kodak).  
 When indicated, S100A4, or BSA as control, were included in the kinase 
reaction. Densitometric quantitation of the autoradiographs was done on a GS-800 
densitometer (Bio-Rad) using the Quantity One software (Bio-Rad). Densitometric 
values are expressed in arbitrary units calculated from background non-saturated 
signals. 
A biotinylated peptide containing the rat CD5 ITAM-like sequence (Biot-
AASHVDNEYSQPPRNSRLSAYPALE-OH, purchased from New England Peptide) 
was also included as a Fyn or Lck substrate in the reaction mix at a final 
concentration of 0.5 μg/μl. For precipitation of the biotin-labeled CD5 peptide, the 
beads containing the immune complexes were boiled for 5 min in 2% SDS and 
diluted 8-fold with lysis buffer. After centrifugation, supernatants were recovered and 
pre-cleared for 30 min with 100 μl protein A-Sepharose beads. The CD5-peptide was 
recovered using neutravidin beads (Thermo Scientific) and the incorporated [γ-32P]-
ATP was measured in a Beckman liquid scintillation counter.  
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Western-Blot 
Proteins were separated by SDS-PAGE under reducing or non-reducing 
conditions as deemed appropriated and then transferred in a semi-dry iBlot system 
to a nitrocellulose membrane (Life Technologies). Membranes were blocked in TBS, 
0.2 % (v/v), Tween 20 (TBS-T), containing 5 % (w/v) non-fat dried milk, probed with 
unconjugated primary antibody for 1 hour and revealed with HRP-conjugated goat 
anti-mouse or goat anti-rabbit IgG (both from Sigma), or IgGVeriBlot anti-rabbit 
(Abcam) at appropriate dilutions. Membranes were washed thoroughly with TBS-
Tween. Immunoblots were developed using ECL (Amersham Biosciences) and 
exposed to BioMax MR films (Kodak). 
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DESIGN OF THE CD5 MUTANTS 
 
CD5 is an important inhibitory receptor that down-modulates signaling and 
thus controls the strength of T cell activation 68. As CD5 has no intrinsic enzymatic 
activity, it is believed that its function is mediated by molecular associations it 
establishes with downstream effectors. A main mechanism of transient molecular 
interactions in signal transduction propagation involves the coupling of molecules 
containing SH2 domains that bind to phosphorylated tyrosine residues of the 
cytoplasmic part of important surface receptors. A main interest is therefore to 
characterize the molecular interactions established by individual phosphotyrosines 
of the cytoplasmic tail of CD5, and using mutational studies, to establish the impact 
of these very localized associations in the cellular function during activation.  
Among the four tyrosine residues present in the cytoplasmic tail of CD5, Y429 
andY463 are known to be highly phosphorylated upon T cell activation 58, 59. On the 
other hand, tandemly arranged ITAM-lookalike tyrosines Y429 and Y441 have been 
described to be determinant for the inhibitory effect of CD5 in both B and T cells 80, 
89. Our previous unpublished results suggested that deletion of a sequence 
encompassing the ITAM-like motif also resulted in the abrogation of CD5 recruitment 
to the IS. 
 Taking these data into account, we produced a set of constructs to analyze 
the molecular function of CD5 (Fig. 6): one containing the cDNA coding for full-
length CD5 (CD5 WT), one CD5 mutant having the ITAM-like sequence deleted 
(CD5 ΔITAM), and two constructs with single of Y429F or Y441F substitutions (CD5 
Y429F and CD5 Y441F), where tyrosine residues were individually substituted by 
phenylalanine, a structurally similar amino acid that is however unable of being 
phosphorylated and to serve as binding site for other proteins. All constructs were 
inserted into the pHR plasmid to induce protein expression through lentiviral 
infection. 
In addition, we designed two further constructs, one resulting in the complete 
removal of the cytoplasmic domain (CD5 ΔCyt, to be used as a control non-signaling 
CD5), and one other where we removed the sequence coding for the extracellular 
part (CD5 Headless, with the removal of the three SRCR domains) to evaluate 
whether CD5 was able to be translocated to the immunological synapse without 
ligand binding. Depending on the projected experiments, constructs (except the CD5 
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Headless mutant) were designed to both contain or not mCitrine, a monomeric 
fluorescent YFP variant, fused to the C-terminal part of CD5 (Fig. 8). 
 
 
 
 
 
 
CD5, TCR/CD3 AND CD6 EXPRESSION ON TRANSFECTED JTAG CELLS 
 
E6.1 Jurkat cells are an immortalized T cell leukemia line 115 and probably the 
most widely used model for in vitro T cell signaling research. JTAg cells derive from 
E6.1, but they were used in these experiments because they lack constitutive CD5 
expression 114.  
In order to evaluate the effect of lentiviral infection per se, JTAg cells were 
transduced with empty pHR vector. These cells were analyzed by flow cytometry 
and compared with untransduced JTAg cells for the expression of relevant surface 
markers. During our experiments, we closely monitored the expression of the 
TCR/CD3 complex, due to its vital role on T cell activation. We also analyzed the 
expression of CD6 that, like CD5, has a modulatory function on T cell signaling, and 
that has been reported to inversely change its expression to compensate for CD5 
fluctuations. 
 
 CD5 WT 
 
CD5 ΔITAM 
    CD5 Y429F 
CD5 Y441F 
CD5 ΔCyt
CD5 Headless
 
pHR-Citrine 
 
pHR 
Figure 8. Establishing stable cell lines expressing CD5 mutants. Schematic representation of CD5 wild 
type (WT) and CD5 mutants: one with the ITAM-like sequence deleted; two constructs where each of the 
tyrosine residues 429 and 441 were individually substituted by phenylalanine; CD5 ΔCyt without the 
cytoplasmic tail; and CD5 Headless where the extracellular part was deleted. On the left side there are 
represented the constructs with mCitrine fused to the C-terminus of CD5 and on the right side the constructs 
without citrine. Lentiviral mediated delivery of the pHR plasmid was used to drive the expression of these CD5 
molecules into CD5 deficient-JTAg cells. 
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 Our initial analyses indicated that in fact some changes in the expression of, 
in particular, CD3 could be observed following transduction using the empty pHR 
vector, reinforcing our need to closely evaluate cell surface receptor variations (Fig. 
9).  
In light of these variations induced by the pHR vector, cells expressing the 
CD5ΔCyt construct schematized in Figure 8 are perhaps a better “negative” control 
than untransduced cells, given that CD5ΔCyt does not signal but the cells have 
gone through the same experimental procedure and infection protocol like the cells 
expressing all the other signaling-competent CD5 molecules. 
 
 
 
  
 JTAg cells were then transduced with all the CD5 constructs using the culture 
supernatants of 293T cells transfected for 72 h. CD3 expression was analyzed by 
flow cytometry in all cell lines and, as feared, its expression varied considerably 
(Fig. 10). Moreover, the expression of the CD5 molecules was also inconsistent, 
although it was possible to correct the levels of expression using different 
concentration of virus supernatant during infection. 
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Figure 9. Effect of lentiviral infection on the expression of surface markers (CD3, CD5 and CD6). 
Lentiviral-mediated delivery of the pHR plasmid induced some variation in the expression of surface 
markers, most noticeably a detectable decrease of surface TCR/CD3. 
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 In order to obtain all cells with the closest CD3 and mutant-CD5 expression 
levels, we decided to sort the cells, gating for equivalent patterns of expression. 
Cells were stained for CD5 and CD3 using respectively Y-2/178 followed by donkey 
anti-mouse IgG-AlexaFluor 647 conjugated, and mouse anti-human CD3 conjugated 
with PerCP-Cy5.5, and sorting was obtained using a FACSAria 1 cell sorter. In the 
case where CD5 is fused with citrine, the citrine fluorescence could also be used to 
perform the sorting.  
 After sorting, expression of the surface markers was again evaluated. As 
shown in Figure 11, there was in general a significant improvement in terms of 
homogeneity of the expression of CD3 and of the different CD5 mutants, although 
100 101 102 103 104
CD5
0
50
100
150
200
250
# 
C
el
ls
100 101 102 103 104
CD6
0
100
200
300
# 
C
el
ls
100 101 102 103 104
CD3
0
100
200
300
# 
C
el
ls
CD5 deltaCyt
CD5 Y441F
CD5 Y429F
CD5 deltaITAM
CD5 WT
JTAg untransfected
Isotype Control
100 101 102 103 104
CD5
0
50
100
150
200
# 
C
el
ls
100 101 102 103 104
CD6
0
50
100
150
200
# 
C
el
ls
100 101 102 103 104
CD3
0
50
100
150
200
# 
C
el
ls
 
A 
 
B 
 
Figure 10. Expressing of relevant cell surface markers in JTAg cells transduced with CD5 
variants. Cells expressing wild type CD5 and CD5 mutants without (A) or with mCitrine fused to the C-
terminus (B) were analyzed by flow cytometry. The expression of endogenous CD3 and CD6, and the 
exogenous CD5 molecules is shown. 
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some minor variations could still be observed. The expression of CD6 was overall 
more stable and homogeneous before or after sorting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE CD5 HEADLESS MUTANT IS EXPRESSED AT THE PLASMA MEMBRANE 
 
The CD5 mutant lacking the extracellular domain, which we have called CD5 
Headless, was designed with one main goal: to evaluate whether CD5 is able to 
localize at the immunological synapse in the absence of an APC-expressed CD5-
ligand. This mutant only contains 10 amino acids of the extracellular part 
(corresponding to the linker between the third SRCR domain and the 
transmembranar sequence) but that are nonetheless required for stable expression, 
0 102 103 104 105
CD5
0
50
100
150
200
250
# 
C
el
ls
0 102 103 104 105
CD6
0
50
100
150
200
250
# 
C
el
ls
0 102 103 104 105
CD3
0
50
100
150
200
250
# 
C
el
ls
 
A 
0 102 103 104 105
CD5
0
50
100
150
200
250
# 
C
el
ls
0 102 103 104 105
CD6
0
50
100
150
200
250
# 
C
el
ls
0 102 103 104 105
CD3
0
50
100
150
200
250
# 
C
el
ls
 
B 
CD5 deltaCyt
CD5 Y441F
CD5 Y429F
CD5 deltaITAM
CD5 WT
JTAg untransfected
Isotype Control
Figure 11. CD3, CD5 and CD6 levels in JTAg-transduced cells after cell sorting. Cells 
expressing wild type CD5 and CD5 mutants without (A) or with mCitrine fused to the C-terminus (B) 
were analyzed by flow cytometry after cell sorting selecting equivalent levels of CD3 and CD5. The 
expression of endogenous CD3 and CD6, and the exogenous CD5 molecules is shown. 
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and together with the transmembrane sequence ensure the attachment to the 
plasma membrane. Given that the mutant lacks the extracellular part and therefore 
the binding site for the anti-CD5 mAb used for staining, we could only track its 
expression by the fluorescence detection of the citrine part of the chimera. 
 Nevertheless, transduced JTAg cells were analyzed for the expression of CD6 
and CD3 using mAbs, before and after CD5-citrine + CD3 sorting (Fig. 12). However, 
it was not evident whether CD5 Headless was being expressed at the cell surface. 
To determine the cellular localization of the mutant, we analyzed its expression by 
fluorescence microscopy. As observed in Figure 13, CD5 Headless can be 
addressed to the plasma membrane. We could also observe a significant amount of 
the citrine-derived signal localized near the nucleus (identified by DAPI staining), 
which could correspond to CD5 Headless molecules being localized at the Golgi 
complex, where CD5 possibly accumulates before being transported to the cell 
membrane. 
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Figure 12.Expression of cell surface markers in CD5 Headless-expressing JTAg cells. Flow cytometry 
analysis using mAbs against CD6 or CD3 showing the amount of protein expression at the cell surface 
before (A) and after (B) sorting. The expression of CD6 was slightly changed but that of CD3 improved 
significantly regarding homogeneity.   
Before Sorting After Sorting 
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The next step in our programmed plan was to incubate these cells with 
superantigen-loaded Raji cells used as APC, and track the movement of CD5, or 
lack of it, towards the immunological synapse. These procedures were executed but 
in the initial experiments we were not able to have the system perfectly adjusted, 
with no optimal T cell to APC ratios, and therefore no usable results could be 
collected in due time for presentation in this thesis. 
 
CD5 AS A REGULATORY MOLECULE OF T CELL ACTIVATION 
 
 The mechanism of CD5-mediated inhibition has not been fully clarified, but 
ample evidence suggests that phosphorylation of some of its cytoplasmic tyrosine 
residues and coupling of downstream inhibitory enzymes are involved. In order to 
measure the activation status of our cellular models expressing CD5 mutants, and 
thus to assign specific effects to the mutated tyrosine residues, we performed 
several assays addressing specific marks of activation: immediate, early and late 
signaling events, by measuring intracellular calcium influx, CD69 expression and 
proliferation rates, respectively. 
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Figure 13. CD5 Headless localizes at the plasma membrane in stably transduced JTAg cells. Cells 
were transduced with pHR vectors containing constructs encoding wild type CD5 or CD5 devoid of its 
extracellular domain, both fused to mCitrine at their C-termini. The localization of CD5 WT (upper panels) or 
CD5 Headless (lower panels) was visualized by fluorescence microscopy showing CD5 molecules in green, 
in paraformaldehyde fixed cells. Cell nuclei are stained with DAPI and visualized in blue. Scale bar: 20 μm. 
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CD5-mediated calcium flux upon T cell activation 
Intracellular Ca2+ release is an early occurrence in T cell activation, reflecting 
the initial stages upon TCR triggering, namely the phosphorylation and activation of 
PLC-γ1 that directly results in phospholipid hydrolysis and calcium mobilization 5. 
Free intracellular Ca2+ can be detected by Fluo-4, a non-fluorescence compound 
that when binds to free Ca2+ emits fluorescence 116. In these assays, our CD5-citrine 
chimeras cannot be used as the emission waves of the two fluorochromes overlap.  
JTAg cells expressing the different CD5 mutants were incubated with Fluo-4, 
and then activated with the addition of OKT3 to the medium. Calcium release was 
monitored by flow cytometry, with data collection starting 1 min prior to the actual 
addition of the stimulating antibody (Fig. 14). No differences were observed in the 
responses between untransfected cells and cells expressing CD5 ΔCyt, as 
expected, confirming the usefulness of this cytoplasmic tailless CD5 mutant as a 
negative control (Fig. 14A). 
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Figure 14. The cytoplasmic tail of CD5 mediates the inhibition of calcium influx upon T cell 
activation. JTAg cells were incubated with Fluo-4 and analyzed by FACS during 300 sec. Activating CD3 
mAb (OKT3) was added at 60 s leading to calcium influx. At the end of each assay, ionomycin was added 
to fully open calcium channels to give a measure of total cellular calcium. A. Levels of intracellular calcium 
in JTAg CD5 ΔCyt cells comparing to calcium release in untransduced JTAg cells. B. Calcium fluxes 
triggered upon TCR/CD3 stimulation with OKT3 in JTAg cells expressing the different CD5 variants. 
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Analyzing calcium responses for the cells expressing the different CD5 
mutants, it is noticeable that the expression of a complete unmodified CD5 form 
results in a marked down regulation of calcium signals (Fig. 14 B). On the other 
hand, the CD5 mutant without the ITAM-like sequence had completely lost the 
inhibitory capacity, and single substitutions of the tyrosine residues resulted in 
partial effects, with the Y429 residue being responsible for most of the observed 
inhibition of calcium signaling (Fig. 14 B). 
 
CD69 expression as a measure of effective T cell activation 
CD69 is a lymphoid antigen that is rapidly induced after T cell activation. This 
molecule is involved in lymphocyte proliferation and other signaling functions, and 
the increase of its expression is regarded as a measure of a second stage of 
activation 117.  
CD69 levels on JTAg cells expressing the different CD5 mutants were 
assessed following the simultaneous stimulation of the TCR/CD3 complex (using 
OKT3) and CD28 (using the 28.2 mAb). An alternative and perhaps stronger 
stimulus was provided in parallel experiments by PHA-P, a lectin that crosslinks 
glycosylated surface proteins, including the TCR, and provokes extensive receptor 
aggregation and cell activation118.  
Cells were activated for 12 h, and then surface CD69 was detected by flow 
cytometry. Upon 12h of activation with PHA-P, 47.1 % of untransduced JTAg cells 
expressed CD69 (Fig. 15A), confirming that JTAg cells are “activatable”, whereas 
less than 10 % of cells were CD69+ following CD3+CD28 stimulation. We 
nevertheless decided to continue the experiments using mAb-mediated stimulation 
given that it is more specific to activate certain receptors and that we are looking for 
a very defined and subtle regulation at the level of surface receptors. 
CD69 expression was thus analyzed in JTAg cells expressing the CD5 
variants following cell activation using CD3+CD28 mAbs (Fig. 15B), and values were 
normalized for cells expressing the non-signaling CD5 mutant ΔCyt (Fig. 15C, 
expressed as fold decrease comparing with JTAg-CD5 ΔCyt). It is apparent that 
compared with the cells expressing CD5 ΔCyt, all other CD5 mutants failed to 
induce CD69 expression. In other words, cells expressing CD5 mutants containing 
the cytoplasmic tail of CD5, either unmodified or mutated, were unable to induce the 
expression of this marker of activation. 
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The role of CD5 in the inhibition of T cell proliferation 
The inhibitory role of CD5 has an impact not only in the early steps of T cell 
activation but also on cell proliferation. To test the effect of CD5 mutants in the 
proliferative capacity of JTAg cells, these were serum-deprived for 24h to 
synchronize cells at the G1 stage of the cell cycle 119 and labeled with CFSE, which 
is a fluorescent compound that covalently binds to intracellular molecules and is 
often used to monitor cell proliferation. Given that when cells divide their 
components are evenly distributed by the daughter cells there is the perceived 
halving of intracellular CFSE in each cell cycle 120. 
 
B 
A 
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Figure 15. CD69 expression in JTAg cells following cell activation. A. CD69 Expression levels of 
untransduced JTAg cells activated with 10 μg/ml PHA-P (purple) or with OKT3+CD28 mAbs (red). CD69 
expression in non-activated cells (cyan) is negative as it overlaps with irrelevant antibody staining (grey filling). 
B. JTAg cells expressing CD5 WT or mutants were activated with 2 μg/ml OKT3 plus 5 μg/ml CD28, and after 
12 h were stained with an anti-CD69 mAb conjugated with APC. Values were normalized to the same 
population in resting conditions. C. Same as in B, with CD69 expression levels in JTAg CD5ΔCyt cells being 
used as reference to which the values for all the other cell lines are obtained. 
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JTAg cells are ever-dividing cells, and to measure the effect of CD5 
expression on changes in the proliferation rate, CFSE values were normalized to 
time 0 (staining and platting of the cells) and to the values obtained with JTAgCD5 
ΔCyt cells, as the CD5 ΔCyt mutant is considered signaling-inactive. The CFSE 
fluorescence levels were analyzed at 24, 48 and 72h, and as shown in Figure 16, 
JTAg CD5 WT cells had the lowest proliferation rate, as expected. JTAg CD5 ΔITAM 
and JTAg CD5 Y429F showed proliferation rates close to 1, suggesting that these 
CD5 mutants had lost the capacity of inhibiting signaling and proliferation. On the 
other hand, JTAg CD5 Y441F cells had a slight decrease in the proliferation rate, 
suggesting that mutation of tyrosine residue 441 had less an effect than the Y429F 
substitution, i.e., Y429 is associated with a slightly higher inhibitory function than 
Y441. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOVEL BINDING PARTNERS THAT POTENTIALLY MEDIATE CD5 FUNCTIONS 
 
During the last years a number of binding partners for CD5 have been 
described, that have helped to unveil the mechanism underlying the CD5-mediated 
inhibitory role. These effectors include enzymes with inhibitory functions such as 
SHP-1, Cbl and RasGAP, as well as molecules, like PI3 kinase or Fyn, that are 
sometimes associated with positive signaling but that in the proper context may 
function to repress activation. We are currently performing, in collaboration with the 
Figure 16. The relative proliferation rate of JTAg cells is influenced by CD5 
mutations. After serum deprivation and cell cycle synchronization, non-stimulated 
JTAg-CD5 cell mutants were labeled with CFSE and their rate of proliferation was 
analysed after 24, 48 and 72 h by flow cytometry. The results were normalized 
considering the proliferation rate of the JTAg CD5 ΔCyt cells as 1. 
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group of Simon Davis in Oxford, a wide-range screening of SH2 domain-containing 
molecules that associate with synthetic peptides that contain the different 
phosphorylated tyrosine residues of the cytoplasmic tail of CD5. In another direction, 
we are additionally searching for CD5-binding partners whose interaction with CD5 
is not dependent on phosphotyrosine-SH2 interactions. 
 
Crk: a protein adaptader that may relay CD5 signals 
During our screening of SH2-containing proteins that interact with CD5, using 
surface plasmon resonance, we have confirmed a direct interaction of CD5 
phosphotyrosines with the SH2 domains of Fyn, PI3 kinase, RasGAP, SHP-1 and 
Cbl. All these interactions display high affinities of binding of SH2 domains with 
individual or doubly phosphorylated tyrosines. An additional hit, and in fact one that 
had one of the strongest affinities, was the SH2 domain of the adapter protein Crk.  
In T cells and upon TCR stimulation, Crk participates in a complex that also 
involves Cbl93, 121. However, given that it is an adapter and it is quite difficult to 
establish which other partners Crk binds to once it docks onto CD5, our strategy will 
involve in the future to use our CD5 mutants containing Y-to-F substitutions to look 
for the cellular effects resulting from the mutation of the appropriate tyrosine 
residues of CD5, as well as from the down regulation of Crk itself. For the time 
being, we first needed to confirm that in our T cell model Crk does in fact associate 
with CD5 upon cellular stimulation. 
 We have used E6.1 Jurkat cells and stimulated them with anti-CD3 (OKT3) 
antibodies. In these specific activation experiments we have used F(ab’)2 fragments 
of OKT3 because they still contain the two arms including the variable regions and 
therefore can induce TCR/CD3 dimerization, but lack the Fc portion and thus are not 
precipitated in the presence of protein A-Sepharose beads. In parallel, we 
stimulated E6.1 cells with sodium pervanadate, which induces a global inhibition of 
phosphatase activity, allowing kinases to become active and drive cell activation 122. 
After activation with OKT3-F (ab’)2 or pervanadate for 2 and 10 min, cells 
were lysed with detergent and CD5 was immunoprecipitated using the anti-CD5 mAb 
Y-2/178 and protein A-Sepharose beads. Immune complexes were washed, heated, 
and loaded onto SDS-PAGE gels. After electrophoresis and western blotting we 
detected Crk in CD5 immunoprecipitates using an anti-Crk polyclonal antibody, 
confirming an interaction between CD5 and Crk in Jurkat cells upon cell activation 
(Fig. 17). 
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S100A4 associates with, and affects the kinase activity of, the Src-
tyrosine kinases Lck and Fyn 
 Lck, and to a lesser extent Fyn, are the protein tyrosine kinases which, 
concomitantly with the initiation of TCR-mediated signal, are involved in the 
phosphorylation of CD5 57. In collaboration with the group of Maria Bokarewa in 
Gothenburg, we have established that deficiency of the cytoplasmic calcium binding 
protein S100A4 results in insufficient CD5 expression and in increased T cell 
proliferation. We therefore asked whether the S100A4 protein could directly obstruct 
the activity of the Src-tyrosine kinases towards CD5.  
 Using polyclonal antibodies, we immunoprecipitated Lck and Fyn from lysates 
of non-stimulated E6.1 Jurkat cells and tested whether these kinases had their CD5 
phosphorylation affected by the presence of exogenous S100A4. Kinase activities 
were assessed using [γ-32P]-ATP as source of the phosphate groups and as 
phosphorylation target we used a synthetic biotinylated peptide corresponding to the 
C-terminal part of the CD5 cytodomain and containing the ITAM-like motif. After the 
kinase reactions in the presence or different amounts of recombinant S100A4, the 
CD5 peptide was pulled down with neutravidin beads and the radioactivity 
incorporated into the peptide was measured in a liquid scintillation counter.  
Recombinant S100A4 induced a remarkable decrease of peptide 
phosphorylation mediated by Lck, while it provoked an increase in the 
Figure 17. Crk co-precipitates with CD5 in Jurkat cells. CD5 were 
immunoprecipitated from cell lysates of non-stimulated and stimulatd Jurkat 
cells. In the upper panel stimulation via TCR/CD3 using OKT3, at timepoint 2 
and 10 min. In the lower panel, stimulation with sodium pervanadate for 2 
and 10 min. Immunoblot of CD5 is used as a loading control. 
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phosphorylation regulated by Fyn (Fig. 18A). This effect of S100A4 was calcium-
independent, since the addition of CaCl2 had only marginal effect of the 
phosphorylation of the peptides. Replacement of S100A4 by control BSA restored 
completely (for Fyn) or most (for Lck) the peptide phosphorylation.  
 To clarify whether these effects were due to changes in the kinases activities 
by S100A4 or to a possible block/interference of the phosphorylation sites by 
S100A4 binding to the peptide, we immunoprecipitated the kinases directly from the 
reactions and assessed their autophosphorylation capacity. As seen by SDS-PAGE 
and autoradiography, S100A4 at 0.5 mg/ml provoked a marked decrease of the Lck 
activity (by 55 %), while the activity of Fyn was simultaneously increased by over 
30%, as indicated by the densitometry values under each lane (Fig. 18B). 
Substitution of S100A4 by BSA reverted the activity of the kinases to their original 
levels. 
 A direct interaction of S100A4 with both Lck and Fyn was confirmed by co-
precipitation of Lck and Fyn with recombinant S100A4 (at 0.1 mg/ml) from lysates of 
Jurkat cells. Antibodies against S100A4 and Csk were used as positive and negative 
controls, respectively. Immunoblotting of the immunoprecipitates with an anti-
S100A4 antibody confirmed that S100A4 was included in the Lck and Fyn 
immunoprecipitates (Fig. 18C, upper panel). Reciprocally, Fyn was visible in S100A4 
immunoprecipitates (Figure 18C, lower panel). However, no Lck could be detected in 
S100A4 immune complexes (Fig. 18C, middle panel). Given that recombinant 
S100A4 is present in large excess relatively to endogenous proteins in this assay, 
and that in Jurkat cells Fyn is expressed at much lower levels than Lck, these 
combined results suggest that the interaction of S100A4 with Fyn is significantly 
stronger than that of S100A4 with Lck. 
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Figure 18. S100A4 co-precipitates with Src-tyrosine kinases Lck and Fyn and changes their kinase 
activity.A. Lck and Fyn were immunoprecipitated from cell lysates of non-stimulated Jurkat cells. The kinase 
activities of Lck and Fyn were assessed in the presence or absence of recombinant S100A4 or control mBSA 
using a 25 amino acid-long synthetic biotinylated peptide corresponding to the rat CD5 sequence and 
containing tyrosines 453 and 465 of CD5 and [γ-32P]-ATP as source of the phosphate groups. After the kinase 
reactions, the peptide was pulled down with neutravidin beads and the radioactivity incorporated into the 
peptide was measured in a liquid scintillation counter. The experiments performed in Ca-free and CaCl2 
enriched buffers gave similar results. B. Changes in the kinase activity by addition of recombinant S100A4 
were assessed by autophosphorylation of kinases. The immunoprecipitated Lck and Fyn kinases were 
subjected to SDS-PAGE and autoradiography (top panels) and to western blotting using anti-Lck and anti-Fyn 
antibodies (lower panels, left and right, respectively). Values under the lanes of the top panels represent 
densitometry of the signals obtained in the autoradiography normalized with the densitometry values obtained 
from the immunoblots against Lck or Fyn, that are used as loading controls. C. Lck and Fyn were 
immunoprecipitated from lysates of Jurkat cells in the presence of recombinant S100A4 at 0.1 mg/ml. 
Antibodies against S100A4 and Csk (a tyrosine kinase that phosphorylates the inhibitory C-terminal tyrosine 
residue of Lck and Fyn) were used as positive and negative controls, respectively. Western blots were 
performed and indicated the presence of S100A4, Lck or Fyn in the different immunoprecipitates. 
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The CD5 glycoprotein is a T cell surface antigen described to have different 
roles in immunity, such as regulation of cell death 78, 114, 123, acting as PRR in the 
recognition of some fungi-wall PAMPs 124, and as a modulator of the T and B 
lymphocyte activation and differentiation 68, 70, 71. This role as a regulator of 
lymphocyte signaling suggests that CD5 may have an underlying role in the 
development of autoimmunity 125, cancer 114 (relating to the capacity to prevent cell 
death) and other diseases. In this work we have contributed to unveil and dissect 
some questions regarding the CD5 inhibitory role in T cell activation.  
CD5 contains four tyrosine residues in its cytoplasmic tail; two of these are 
within in a sequence that resembles the consensus motif for an ITAM 55. This 
pseudo-ITAM has, nonetheless, been described to be determinant for the inhibitory 
effect of CD5 in B and T cells 80, 89 and in our previous unpublished results, we 
determined that a CD5 mutant without this sequence could not localize at the IS 
upon antigenic challenge. 
To analyze the effect of CD5 tyrosine residues in cell signaling, JTAgCD5-
deficient cells were transduced with the CD5-coding cDNAmutants described in 
Figure 8. The stable cell lines resulting from the transductions express either a full 
length CD5 form (CD5 WT), a CD5 molecule lacking the ITAM-like sequence (CD5 
ΔITAM), two forms where each of the tyrosines were substituted by a phenylalanine, 
and two other complementaryvariants: one that lackst he complete cytoplasmic tail 
(CD5 ΔCyt), functioning as a signaling negative control, and another one that is 
chopped off the extracellular domain. The latter mutant, CD5 Headless, is not 
capable of establishing extracellular interactions with putative ligands expressed on 
antigen presenting cells, 
The transduction of the cDNAs through the lentiviral system induced 
unwanted variations in the levels of expression of surface markers like CD6, and 
more noticeably CD3. However, the control of the expression of surface markers not 
directly involved in the transfection procedures is critical for the correct setting-up of 
the system. It was very important to obtain cell lines stably transfected and with 
similar levels of important receptors like CD3 and CD6, apart form the “inserted” 
CD5 mutants, to confidently assign variations in the signals obtained to the specific 
CD5 mutations. To this end, we performed FACS sorting frequently and before the 
“final” experiments. 
A major conclusion from this type of observations in the preliminary 
experiments was that untransduced JTAg cells were not the proper negative control. 
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Rather, JTAg cells expressing CD5 ΔCyt, a non-signaling mutant of CD5, were 
elected as the reference cells as they had experienced all the transformation steps 
that all other cell lines expressing the CD5 mutants did. In this context, all cell lines 
have the same background so differences between their responses will be 
attributable to the CD5 mutations. 
 
Can CD5 localize at the immunological synapse in the absence of an 
APC-expressed CD5-ligand? 
During IS formation, CD5 is one of the molecules that co-localizes with 
TCR/CD3 complexes and is able to attenuate T cell signaling without damaging IS 
formation 89. We have observed that when the extracellular part of CD5 is not able to 
interact with ligands in the APC, it is still able to translocate to the IS in a 
cytoplasmic tail dependent manner, relying namely the presence of key motifs in this 
domain. 
The CD5 Headless mutant was designed to evaluate whether CD5 is able to 
localize at the IS without its extracellular part and consequently without the binding 
of a putative CD5 ligand expressed in APC or establishing other interactions with 
molecules expressed on the T cell surface. 
Although we have not still completed this line of research, we have 
established the cell line to be usable in these experiments. As shown in Figure 13, 
the CD5 Headless mutant is stably expressed and can be addressed to the plasma 
membrane. The studies to establish the localization of CD5 Headless during APC-
antigen presentation are ongoing, with JTAg CD5 Headless cells being stimulated 
with Raji B cells that present a superantigen in order to establish an IS. The final 
goal is to perform these assays with video imaging for understanding the kinetics of 
CD5 Headless recruitment (or not) to the contact zone. 
 
CD5-mediated calcium flux upon T cell activation 
Regarding the function of CD5 as a modulator of T cell activation, we have 
already established the molecular systems to be used, and preliminary performed 
different assays in order to identify the mechanisms used and molecules involved in 
the specific stages of activation. 
One earliest event is intracellular calcium influx, which corresponds to a very 
rapid calcium mobilization upon TCR stimulation with the OKT3 monoclonal 
antibody. In Figure 14A, we could prove that JTAg cells transduced with the 
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cytoplasmic tailless CD5 mutant can be used as a good negative control, displaying 
a very similar activation profile compared with the JTAg untransfected cells. 
Interestingly, when we delete the ITAM-like motif, the inhibitory pattern 
observed in the CD5 WT form is completely lost, resulting in the cancellation of 
inhibition and in the generation of high levels of intracellular calcium. These results 
confirm the inhibitory role described for the ITAM-like sequence of CD5 80, 89. We 
have gone deeper in the analysis searching for the inhibitory determinants, and have 
observed that substitution of the Y429 residue by a phenylalanine leads to higher 
calcium influx compared with the substitution in the Y441 residue, indicating that 
Y429 is the main responsible for calcium flux inhibition mediated by CD5. However, 
the calcium signals observed in the JTAg CD5 Y429F cells were not as high as 
those of the CD5 ΔITAM expressing cells, suggesting that the other tyrosine residue 
(Y441) might also contribute to signal inhibition, which we in fact did observe (Fig. 
14B). We can therefore suggest that both tyrosine residues act in a related and 
cumulative way to induce full calcium mobilization inhibition.  
 
CD69 expression as a measure of effective T cell activation 
The analysis of CD69 expression, which is a surrogate marker of T-cell 
responsiveness to mitogen and antigen stimulation, is commonly used as a measure 
of T-lymphocyte activation 126. In our experiments we evaluated CD69 expression 
upon activation for 12 h via the TCR/CD3 complex and CD28 (Fig. 15A). However, 
the level of activation was very low, with less than 10% of the cells having increased 
CD69 expression. This low reactivity could not be fully accounted by an innate low 
responsiveness of the cells, as these could be activated to a larger extent with the 
use of the mitogenic lectin PHA-P. Nevertheless, these values (~50%) are still low, 
so this protocol should be optimized, perhaps testing different concentrations of the 
agonists or longer periods of stimulation. For the purpose of our study, we are also 
planning to use a more physiological and directed mode of activation using 
superantigen-loaded APC cells, such as Raji cells, which will be recognized by our 
mutant CD5-expressing Jurkat cells. 
Despite the low percentage of CD69 positive cells obtained after activation, 
we continued with the planned experiments and CD69 levels in activated JTAg CD5-
expressing cells were normalized to the values of the corresponding cells in the non-
activated state (Fig.15B). Our results again demonstrated that the deletion of the 
complete cytoplasmic tail (CD5ΔCyt mutant) resulted in CD5 losing its inhibitory 
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effect and cells become more responsive to stimulation and express higher CD69 
levels. However, with all other CD5 mutants, JTAg cells did not increase CD69 
expression. This may suggest that the sequences or motifs regulating calcium-
dependent signaling and CD69 expression are different in the CD5 molecule and 
that none of the mutations we used excluded the appropriate signals relating to the 
control of CD69 expression. 
 
The role of CD5 in the inhibition of T cell proliferation 
Proliferation is one of the direct consequences of the T cell activation. 
Looking to CD5 as an inhibitor of the T cell response, it is expected that the 
presence of this molecule in the cell surface leads to a decrease intracellular 
proliferation. Therefore, we investigated the proliferation rate in JTAg CD5 cell lines 
by staining the cells with CFSE.  
In order to have most cells at the same stage of the cell cycle, cells were 
synchronized by deprivation of serum, which contains growth factors important to 
the transition between G0 quiescence and early G1 127. Other methods are available 
to synchronize cells, such as pharmacological agents or, more physiologically, by 
contact inhibition and centrifugal elutriation 128. 
As observed in Figure 14, JTAg CD5 WT cells proliferate less than the 
reference JTAg CD5 ΔCyt cells (with values assigned as 1), followed by the mutant 
expressing theCD5-Y441F substitution. This indicates that, in line wit the results 
from the calcium assays, the substitution in the Y441 residue results in less 
inhibition cancellation than the Y429F substitution. On the other hand, the CD5 
mutant that lacks the ITAM-like sequence is the one that displays, upon 48 h and 72 
h, a more similar response to the reference, as expected given the described role of 
the ITAM-like sequence.  
Taken this together, the calcium and proliferation results are concordant and 
confirm the inhibitory role of the ITAM sequence, and more precisely, of the Y429 
residue, although the other tyrosine may also play a somewhat lesser part. 
There are experiments still in line to be performed: to analyze proliferation 
rates in mAb or mitogenic-activated cells, measure IL-2 production (a cytokine 
normally secreted by T cells during an immune response to promoted growth, 
proliferation and differentiation 129, 130) and evaluate the capacity of CD5-Y429F to 
translocate to the IS.  
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Search for binding partners that can relay the CD5 function: Crk and 
S100A4 
Several studies have described the interactions between the cytoplasmic tail 
of CD5 and different molecules such as PI3K, RAS GAP and c-Cbl 55, 77, SHP-1 56 
and also Lck 27. We are currently conducting a global phosphotyrosine-SH2 domain 
screening to uncover novel CD5 mediated interactions. Additionally, we are 
exploring other directions and studying CD5 interactions not mediated by tyrosine 
phosphorylation. 
In the former class of interactions, using CD5 peptides containing 
phosphorylated tyrosine residues, and recombinant SH2 domains of over 50 
different proteins expressed in Jurkat cells, our surface plasmon resonance studies 
suggested the possible interaction between CD5 and the adapter protein Crk. 
Nevertheless, the first step was to confirm that the interaction is held in cellular 
models, which we did in the current study. The CD5-Crk interaction was however 
already detected in resting cells, and did not increase significantly upon cell 
stimulation. This is perhaps one of the flaws of using cell lines that are in permanent 
cycling and where the activation status is not null. We are confident that repeating 
these assays using resting and activated primary T lymphocytes, we will be able to 
see more marked differences, as we have in the past addressing several other 
activation-dependent interactions. 
It is early days to speculate which type of function will Crk bring to CD5, given 
that as an adapter, Crk bridges many other indirect protein-protein interactions. Crk 
does interact with Cbl, but so does CD5 directly. Surely we will have more defined 
ideas once we disrupt the CD5-Crk interaction by mutating the specific tyrosine 
residue (that would nevertheless unwantedly suppress other CD5 interactions 
mediated by that tyrosine) or preferentially when we down-regulate the expression of 
Crk by RNA interference, and then perform a whole battery of experiments testing 
which signaling functions are altered.  
 
Regarding phosphotyrosine-independent interactions, we unraveled a CD5-
S100A4-dependent mechanism of antigen induced T-cell maturation. An S100A4 
deficient mouse has increased lymphocyte proliferation, a maturation of T helper 
cells with low production of IFN-γ and IL17A, low levels of the transcription factor 
RORγt, which is the most important transcription factor for Th17 differentiation, and 
shows a Th17 cell malformation and low expression of CD5 and Fyn. Functionally, 
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the S100A4 knock-out mouse shows also a decrease of morphological signs of 
arthritis and joint damage. Other results obtained by nuclear magnetic resonance 
(NMR) indicated a direct interaction between CD5 and S100A4. 
More importantly, the fact that the phenotype of the S100A4 knockout mouse 
shares many similarities with that of the CD5 deficient mice, such as increase in 
proliferation of lymphocytes and more reactivity to CD3 binding, made us consider to 
address a possible S100A4 effect on CD5 signaling.  
The major function of Fyn in T-cells is the regulation of signaling through TCR 
where it works in synergy with the Src-tyrosine kinase Lck 131. Lck and Fyn are 
known to control TCR signaling through the lymphocyte receptor CD5 (reviewed in 
81, 132). The C-terminal phosphorylation of CD5 by Fyn has been recognized as a 
mechanism required for CD5-dependent regulation of Fyn 60. Additionally, CD5 
signals are critical for the activation of STAT3 and initiation of Th17 development 110. 
We observed, that the deficiency in S100A4 was associated with a smaller 
CD5+CD4+ T-cell population, which had also low levels of the phosphorylated CD5-
Y429 in T cells. A functional consequence of insufficient CD5 in S100A4-deficient 
mice may be found in the enhanced lymphocyte proliferative capacity observed both 
in S100A4 KO and S100A4-shRNA-treated mice. Analogously to S100A4-deficient 
mice, functional CD5 is shown to be essential for the differentiation of naïve T cells 
into Th2 and Th17-cells79, 110. 
The interaction between S100A4 and its target proteins, NMMII, beta-liprin 
and recently the cytoplasmic domain of FcγRIIIA, occurs within PKC or CK2 
sensitive region of the target protein 105, 106, 108, 133. The cytoplasmic tail of CD5 
contains the PKC-sensitive regions at S427 and the CK2 phosphorylation site at its 
C-terminal region 134. A deletion of the C-terminal fragment of CD5 containing CK2-
phosphorylation site resulted in a failure to produce Th2 and Th17-cell subsets 109. A 
binding assay revealed an interaction between S100A4 and a CD5 peptide 
containing the CK2-sensitive sequence resembling the affinity of smaller myosin 
peptides 135. The results of the NMR spectra analysis provided an evidence for the 
physical interaction between the C-terminal-region of the CD5 cytoplasmic domain 
and the EF2 sites of S100A4. A dimerization of the CD5 receptor on the cell surface 
is expected to bring two S100A4 binding sites in each monomer close together and 
enhance the affinity between CD5 and S100A4.  
 In in vitro experiments we show that S100A4 co-precipitates with both Lck 
and Fyn from the cell lysates indicating a direct binding between these proteins (Fig. 
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18). Moreover, this binding had a reciprocal effect on the kinase activity of Fyn and 
Lck. S100A4 reduced Lck-dependent phosphorylation of CD5 to a degree 
comparable with that it increased the kinase activity of Fyn. This provides 
experimental evidence that S100A4 is able to disrupt CD5 complexes at the cell 
surface that could modify some of the receptor’s effects, thus establishing S100A4 
as a regulator of CD5 function. Thus, the absence of S100A4 corresponded to 
highest kinase activity of Lck, which is in agreement with the hyper-proliferation 
state observed in S100A4-deficient lymphocytes and predicted a disruption of Fyn 
activity. Insufficient formation of Th17 cells due to reduced activity of STAT3 and 
poor production of RORγt is consistent with a Fyn-deficient phenotype 136. These 
results suggest that S100A4 is essential for controlling a balance between the 
activities of Lck and Fyn tyrosine kinases. We hypothesized that S100A4 controls 
Lck-dependent T-cell proliferation and Fyn-dependent differentiation of T helper 
subsets through a CD5-dependent mechanism. 
 
 
CONCLUDING REMARKS 
 We have planned and performed a series of experiments to obtain a deeper 
knowledge of the mechanisms that confer an immunomodulatory function to CD5. 
Here we have assigned to the Y429 residue of CD5 a critical role in the inhibition of 
important signaling pathways that arise from the triggering of the TCR. Our research 
is still, however, at an early stage and a better understanding of the function of CD5 
is expected to be gained when we pursue further this line of research 
How exactly CD5 is recruited to the immunological synapse formed between T 
cells and APCs is still not entirely understood, neither is the eventual dependence 
on a putative CD5-ligand of the ligand-mediated CD5 translocation. Also, the 
purpose for the interactions that CD5 establishes with other proteins such as 
S100A4 and Crk, either depending on phosphorylation or other mechanisms, is still 
not fully comprehended. Once we gather more mechanistic insights on the molecular 
function of CD5, we will be able to develop strategies to use CD5 as a therapeutic 
target to modulate immune responses. 
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